JP2010509285A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509285A5
JP2010509285A5 JP2009535729A JP2009535729A JP2010509285A5 JP 2010509285 A5 JP2010509285 A5 JP 2010509285A5 JP 2009535729 A JP2009535729 A JP 2009535729A JP 2009535729 A JP2009535729 A JP 2009535729A JP 2010509285 A5 JP2010509285 A5 JP 2010509285A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heterocyclyl
heteroaryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009535729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509285A (ja
JP5456479B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/062034 external-priority patent/WO2008055947A1/en
Publication of JP2010509285A publication Critical patent/JP2010509285A/ja
Publication of JP2010509285A5 publication Critical patent/JP2010509285A5/ja
Application granted granted Critical
Publication of JP5456479B2 publication Critical patent/JP5456479B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009535729A 2006-11-09 2007-11-08 グルタミニルシクラーゼの新規阻害剤 Expired - Fee Related JP5456479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86498806P 2006-11-09 2006-11-09
US60/864,988 2006-11-09
PCT/EP2007/062034 WO2008055947A1 (en) 2006-11-09 2007-11-08 Novel inhibitors of glutaminyl cyclase

Publications (3)

Publication Number Publication Date
JP2010509285A JP2010509285A (ja) 2010-03-25
JP2010509285A5 true JP2010509285A5 (enExample) 2011-02-17
JP5456479B2 JP5456479B2 (ja) 2014-03-26

Family

ID=39156601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535729A Expired - Fee Related JP5456479B2 (ja) 2006-11-09 2007-11-08 グルタミニルシクラーゼの新規阻害剤

Country Status (5)

Country Link
EP (1) EP2091945B1 (enExample)
JP (1) JP5456479B2 (enExample)
DK (1) DK2091945T3 (enExample)
ES (1) ES2468546T3 (enExample)
WO (1) WO2008055947A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889709B2 (en) 2006-09-21 2014-11-18 Probiodrug Ag Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
JP2010504088A (ja) 2006-09-21 2010-02-12 プロビオドルグ エージー グルタミニルシクラーゼに関連した新規遺伝子
EP3338795A1 (en) 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
EP2344158B1 (en) * 2008-09-04 2017-12-27 Probiodrug AG Use of isoqc inhibitors
SG193828A1 (en) 2008-09-04 2013-10-30 Probiodrug Ag Novel inhibitors
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011076854A1 (en) 2009-12-22 2011-06-30 Probiodrug Ag CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN
JP2013519891A (ja) 2010-02-18 2013-05-30 プロビオドルグ エージー ピログルタミン酸修飾mcp−1を決定することにより炎症性疾患を診断する方法及びグルタミニルシクラーゼの阻害剤のスクリーニング方法
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8409837B2 (en) 2010-08-19 2013-04-02 Probiodrug Ag Crystal structure of glutaminyl cyclase
WO2012110946A1 (en) * 2011-02-17 2012-08-23 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CN103459421B (zh) 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
JP6156845B2 (ja) * 2014-03-04 2017-07-05 株式会社島津製作所 マトリックス支援レーザ脱離イオン化質量分析用マトリックス
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
PL3461819T3 (pl) * 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
CN118019737A (zh) * 2021-06-24 2024-05-10 英矽智能科技知识产权有限公司 用于治疗疾病的β-内酰胺衍生物
WO2025021012A1 (en) * 2023-07-21 2025-01-30 Insilico Medicine Ip Limited Crystalline beta-lactam derivatives and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4806628B2 (ja) * 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
CA2583342A1 (en) * 2004-10-13 2006-04-27 Merck And Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease
MX2008011216A (es) * 2006-03-08 2008-09-11 Hoffmann La Roche 1,5-dihidro-imidazol-2-onas 4-amino-1,5-substituidas.

Similar Documents

Publication Publication Date Title
JP2010511013A5 (enExample)
JP2010509284A5 (enExample)
JP2010509286A5 (enExample)
JP2010520869A5 (enExample)
JP2010524898A5 (enExample)
JP2010524895A5 (enExample)
JP2010524899A5 (enExample)
JP2010524896A5 (enExample)
JP7795521B2 (ja) 抗ウイルス剤としての官能化ペプチド
JP2010524893A5 (enExample)
JP2013521260A5 (enExample)
JP6436205B2 (ja) キノリン誘導体
JP2013521325A5 (enExample)
JP2022501430A5 (enExample)
JP6859323B2 (ja) カルボキシ置換(ヘテロ)芳香環誘導体並びにその調製方法及び使用
JP6708130B2 (ja) キノリン誘導体
JP2014508184A5 (enExample)
JP2013504544A5 (enExample)
US11479550B2 (en) EP4 antagonist
ES2957692T3 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
WO2017216686A1 (en) 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
CN108601766A (zh) Cxcr2抑制剂
US20210346377A1 (en) Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals
JP2014506585A (ja) キナーゼ阻害剤としてのチアゾリルフェニル−ベンゼンスルホンアミド誘導体
JP4432051B2 (ja) N−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法